Clinical Trial Update: The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial investigating intralesional IL-2 and/or BCG for cutaneous metastatic melanoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Metastatic Melanoma

Snippet

Sponsor: Carman Giacomantonio | Conditions: Cutaneous Metastatic Melanoma | Phase 2, Phase 3 | Status: WITHDRAWN